Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma

Anna M. Sawka, Steven Orlov, Jacob Gelberg, Barry Stork, Mark Dowar, Michael Shaytzag, Vafa Tabatabaie, Jeremy L. Freeman, Paul G. Walfish

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background. In well-differentiated thyroid carcinoma, predictors of future positivity of stimulated thyroglobulin (>2 μg/L) after initial radioactive iodine treatment are not known. Methods. In a retrospective study, we used logistic regression analysis to determine whether postoperative stimulated thyroglobulin measurements and pathologic stage independently predict future stimulated thyroglobulin positivity. Results. We followed 141 patients with well-differentiated thyroid carcinoma for a median of 35 months; follow-up stimulated thyroglobulin measurements were positive in 20.6% (29/141). The natural logarithm of the postsurgical stimulated thyro-golobulin was independently associated with a positive stimulated thyroglobulin at long-term follow-up (odds ratio [OR], 4.44; 95% confidence interval [Cl], 2.33-8.45; p < .001); there was a trend for a positive association of TNM stage with positive follow-up stimulated thyroglobulin (p = .054). Lymph node positivity predicted a positive stimulated thyroglobulin in papillary cancer. Conclusions. Stimulated thyroglobulin measurements prior to initial radioactive iodine treatment independently predict future stimulated thyroglobulin positivity in well-differentiated thyroid carcinoma.

Original languageEnglish (US)
Pages (from-to)693-700
Number of pages8
JournalHead and Neck
Volume30
Issue number6
DOIs
StatePublished - Jun 2008
Externally publishedYes

Fingerprint

Thyroglobulin
Thyroid Neoplasms
Iodine
Therapeutics
Retrospective Studies
Logistic Models
Lymph Nodes
Odds Ratio
Regression Analysis
Confidence Intervals

Keywords

  • Clinical predictors
  • Iodine radioisotopes
  • Prognosis
  • regression analysis
  • Thyroglobulin
  • Thyroid carcinoma
  • TNM pathologic stage

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma. / Sawka, Anna M.; Orlov, Steven; Gelberg, Jacob; Stork, Barry; Dowar, Mark; Shaytzag, Michael; Tabatabaie, Vafa; Freeman, Jeremy L.; Walfish, Paul G.

In: Head and Neck, Vol. 30, No. 6, 06.2008, p. 693-700.

Research output: Contribution to journalArticle

Sawka, Anna M. ; Orlov, Steven ; Gelberg, Jacob ; Stork, Barry ; Dowar, Mark ; Shaytzag, Michael ; Tabatabaie, Vafa ; Freeman, Jeremy L. ; Walfish, Paul G. / Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma. In: Head and Neck. 2008 ; Vol. 30, No. 6. pp. 693-700.
@article{e5410ca5403c45da9e78cd42eda280a7,
title = "Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma",
abstract = "Background. In well-differentiated thyroid carcinoma, predictors of future positivity of stimulated thyroglobulin (>2 μg/L) after initial radioactive iodine treatment are not known. Methods. In a retrospective study, we used logistic regression analysis to determine whether postoperative stimulated thyroglobulin measurements and pathologic stage independently predict future stimulated thyroglobulin positivity. Results. We followed 141 patients with well-differentiated thyroid carcinoma for a median of 35 months; follow-up stimulated thyroglobulin measurements were positive in 20.6{\%} (29/141). The natural logarithm of the postsurgical stimulated thyro-golobulin was independently associated with a positive stimulated thyroglobulin at long-term follow-up (odds ratio [OR], 4.44; 95{\%} confidence interval [Cl], 2.33-8.45; p < .001); there was a trend for a positive association of TNM stage with positive follow-up stimulated thyroglobulin (p = .054). Lymph node positivity predicted a positive stimulated thyroglobulin in papillary cancer. Conclusions. Stimulated thyroglobulin measurements prior to initial radioactive iodine treatment independently predict future stimulated thyroglobulin positivity in well-differentiated thyroid carcinoma.",
keywords = "Clinical predictors, Iodine radioisotopes, Prognosis, regression analysis, Thyroglobulin, Thyroid carcinoma, TNM pathologic stage",
author = "Sawka, {Anna M.} and Steven Orlov and Jacob Gelberg and Barry Stork and Mark Dowar and Michael Shaytzag and Vafa Tabatabaie and Freeman, {Jeremy L.} and Walfish, {Paul G.}",
year = "2008",
month = "6",
doi = "10.1002/hed.20755",
language = "English (US)",
volume = "30",
pages = "693--700",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma

AU - Sawka, Anna M.

AU - Orlov, Steven

AU - Gelberg, Jacob

AU - Stork, Barry

AU - Dowar, Mark

AU - Shaytzag, Michael

AU - Tabatabaie, Vafa

AU - Freeman, Jeremy L.

AU - Walfish, Paul G.

PY - 2008/6

Y1 - 2008/6

N2 - Background. In well-differentiated thyroid carcinoma, predictors of future positivity of stimulated thyroglobulin (>2 μg/L) after initial radioactive iodine treatment are not known. Methods. In a retrospective study, we used logistic regression analysis to determine whether postoperative stimulated thyroglobulin measurements and pathologic stage independently predict future stimulated thyroglobulin positivity. Results. We followed 141 patients with well-differentiated thyroid carcinoma for a median of 35 months; follow-up stimulated thyroglobulin measurements were positive in 20.6% (29/141). The natural logarithm of the postsurgical stimulated thyro-golobulin was independently associated with a positive stimulated thyroglobulin at long-term follow-up (odds ratio [OR], 4.44; 95% confidence interval [Cl], 2.33-8.45; p < .001); there was a trend for a positive association of TNM stage with positive follow-up stimulated thyroglobulin (p = .054). Lymph node positivity predicted a positive stimulated thyroglobulin in papillary cancer. Conclusions. Stimulated thyroglobulin measurements prior to initial radioactive iodine treatment independently predict future stimulated thyroglobulin positivity in well-differentiated thyroid carcinoma.

AB - Background. In well-differentiated thyroid carcinoma, predictors of future positivity of stimulated thyroglobulin (>2 μg/L) after initial radioactive iodine treatment are not known. Methods. In a retrospective study, we used logistic regression analysis to determine whether postoperative stimulated thyroglobulin measurements and pathologic stage independently predict future stimulated thyroglobulin positivity. Results. We followed 141 patients with well-differentiated thyroid carcinoma for a median of 35 months; follow-up stimulated thyroglobulin measurements were positive in 20.6% (29/141). The natural logarithm of the postsurgical stimulated thyro-golobulin was independently associated with a positive stimulated thyroglobulin at long-term follow-up (odds ratio [OR], 4.44; 95% confidence interval [Cl], 2.33-8.45; p < .001); there was a trend for a positive association of TNM stage with positive follow-up stimulated thyroglobulin (p = .054). Lymph node positivity predicted a positive stimulated thyroglobulin in papillary cancer. Conclusions. Stimulated thyroglobulin measurements prior to initial radioactive iodine treatment independently predict future stimulated thyroglobulin positivity in well-differentiated thyroid carcinoma.

KW - Clinical predictors

KW - Iodine radioisotopes

KW - Prognosis

KW - regression analysis

KW - Thyroglobulin

KW - Thyroid carcinoma

KW - TNM pathologic stage

UR - http://www.scopus.com/inward/record.url?scp=46249104325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46249104325&partnerID=8YFLogxK

U2 - 10.1002/hed.20755

DO - 10.1002/hed.20755

M3 - Article

VL - 30

SP - 693

EP - 700

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 6

ER -